FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890600126> ?p ?o ?g. }

• W2890600126 endingPage "90" @default.
• W2890600126 startingPage "88" @default.
• W2890600126 abstract "SEE RELATED ARTICLE, P. 79. Patients with a cancer-related disease currently represent 4.2% of all emergency department (ED) visits.1Rivera D.R. Gallicchio L. Brown J. et al.Trends in adult cancer-related emergency department utilization: an analysis of data from the Nationwide Emergency Department Sample.JAMA Oncol. 2017; 3: e172450Crossref PubMed Scopus (98) Google Scholar We can expect this population to increase as the population with a cancer diagnosis in the United States increases from approximately 15 million people to 26 million people by 2040.2Howlader N. Noone A. Krapcho M. et al.SEER Cancer Statistics Review, 1975-2013. SEER, Bethesda, MD2016Google Scholar, 3Bluethmann S.M. Mariotto A.B. Rowland J.H. Anticipating the silver tsunami: prevalence trajectories and comorbidity burden among older cancer survivors in the United States.Cancer Epidemiol Biomarkers Prev. 2016; 25: 1029-1036Crossref PubMed Scopus (590) Google Scholar Emergency physicians are well versed in the provision of acute care to patients with cancer and the potential adverse effects of cytotoxic chemotherapy such as neutropenic fever, tumor lysis syndrome, thrombosis, leukostasis, and hyperviscosity syndrome.4Lewis M.A. Hendrickson A.W. Moynihan T.J. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment.CA Cancer J Clin. 2011; 61: 287-314PubMed Google Scholar However, with the rapid development and deployment of new classes of immune-based cancer therapies, the landscape of cancer treatment and its adverse effects is rapidly changing.5O'Connor J.M. Fessele K.L. Steiner J. et al.Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials.JAMA Oncol. 2018; 4: e180798Crossref PubMed Scopus (68) Google Scholar The article by Majzoub et al6Majzoub I. Qdaisat A. Thein K.Z. et al.Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center.Ann Emerg Med. 2018; (http://doi.org/10.1016/j.annemergmed.2018.04.019)PubMed Google Scholar in this issue of Annals focuses on a new class of such agents, immune checkpoint inhibitors. Immune checkpoint inhibitors are rapidly being approved by the Food and Drug Administration for a variety of cancer types,7UpToDate. Patient selection criteria and toxicities associated with checkpoint inhibitor immunotherapy. Available at: https://www.uptodate.com/contents/patient-selection-criteria-and-toxicities-associated-with-checkpoint-inhibitor-immunotherapy. Accessed June 11, 2018.Google Scholar including melanoma, non–small cell lung cancer, Hodgkin’s lymphoma, and urologic malignancies. Cancer cells can evade the host immune response through complex effects on immune-cell signaling pathways. Checkpoint inhibitors disrupt cell-signaling pathways between T cells and antigen-presenting cells to effectively activate the patient’s immune response, thereby preventing cancer cells from evading the patient’s immune system.8Dine J. Gordon R. Shames Y. et al.Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer.Asia Pac J Oncol Nurs. 2017; 4: 127-135Crossref PubMed Google Scholar, 9Salama A.K. Moschos S.J. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.Ann Oncol. 2017; 28: 57-74Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar Because of this novel mechanism of action, the therapy triggers an immune response to the malignancy. As a result, the expected adverse effects vary significantly from those of cytotoxic chemotherapeutic agents and frequently mimic autoimmune responses, which can affect any organ system and are labeled immune-related adverse events. 10Bayer V. Amaya B. Baniewicz D. et al.Cancer immunotherapy: an evidence-based overview and implications for practice.Clin J Oncol Nurs. 2017; 21: 13-21Crossref PubMed Scopus (20) Google Scholar The clinical picture is thus similar to one of autoimmune disease rather than immunosuppression.11Pallin D.J. Baugh C.W. Postow M.A. et al.Immune-related adverse events in cancer patients.Acad Emerg Med. 2018; 25: 819-827Crossref PubMed Scopus (11) Google Scholar Additionally, symptoms can manifest weeks to months after treatment is initiated or completed, complicating the identification of treatment-related adverse effects. Identifying immune-related adverse events requires emergency providers to have a high degree of clinical suspicion and to obtain a thorough clinical history that includes current and past oncologic treatments. Review articles on immune-related adverse events targeting emergency providers have recently been published and warrant study.11Pallin D.J. Baugh C.W. Postow M.A. et al.Immune-related adverse events in cancer patients.Acad Emerg Med. 2018; 25: 819-827Crossref PubMed Scopus (11) Google Scholar, 12Simmons D. Lang E. The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors.Cureus. 2017; 9: e1774PubMed Google Scholar The article by Majzoub et al6Majzoub I. Qdaisat A. Thein K.Z. et al.Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center.Ann Emerg Med. 2018; (http://doi.org/10.1016/j.annemergmed.2018.04.019)PubMed Google Scholar provides the first look at patients with specific immune-related adverse events and presenting to the ED of a large cancer center. They found that a quarter of ED patients receiving immune checkpoint inhibitors presented with an immune-related adverse event; the most common were consistent with those found in other settings, including diarrhea or colitis, pneumonitis, and dermatitis. Rarer immune-related adverse events were also found, including potentially life-threatening hypophysitis, myocarditis, and vasculitis. The potential presence of immune-related adverse events necessitates a new approach to the diagnosis, treatment, and disposition of patients receiving immune checkpoint inhibitors and presenting to the ED. For example, no longer can dyspnea be considered most likely caused by pneumonia or pulmonary embolus; the possibility of immune-mediated pneumonitis must be considered as well. Likewise, for patients with chest pain, myocarditis and pericarditis must be considered; and for patients with headache, hypophysitis. Traditional laboratory-value red flags, such as neutropenia, are not likely to be present in these patients. Education in regard to these new therapeutics is essential for all emergency providers and should be prioritized. In an effort to aid in the identification of immune-related adverse events and to improve care coordination, many cancer centers are providing patients with wallet cards that list their current medications and potential adverse effects requiring monitoring.13Rubin K.M. Understanding immune checkpoint inhibitors for effective patient care.Clin J Oncol Nurs. 2015; 19: 709-717Crossref PubMed Scopus (15) Google Scholar Because this tool could greatly improve the acute care of patients receiving immune checkpoint inhibitors, emergency providers should establish a dialogue with their oncologist colleagues to advocate such cards to streamline communication. Equally challenging to the identification of immune-related adverse events is determining the next best course of treatment. To address this question, the American Society of Clinical Oncology published comprehensive guidelines in February 2018 targeting an audience that includes emergency medicine providers.14Brahmer J.R. Lacchetti C. Schneider B.J. et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2018; 36: 1714-1768Crossref PubMed Scopus (1957) Google Scholar These guidelines provide diagnostic definitions and treatment recommendations for immune-related adverse events according to the severity of the patient’s presentation. The critical point for the emergency physician is that the treatment and disposition decisions should be made in conjunction with an oncologist. Treatment and disposition depend on the immune-related adverse event type, and severity and can range from discontinuation of therapy to administration of oral or intravenous systemic steroids. Because steroids may inhibit the immune checkpoint inhibitor’s mechanism of action, they should be administered only in life-threatening situations or in consultation with the patient’s primary oncologist and the American Society of Clinical Oncology guidelines. Combination immune checkpoint inhibitor therapies are also becoming increasingly common among patients with melanoma and non–small cell lung cancer.9Salama A.K. Moschos S.J. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.Ann Oncol. 2017; 28: 57-74Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar Combination immune checkpoint inhibitor therapy has been associated with higher rates of immune-related adverse events than single-agent immune checkpoint inhibitor regimens.15Hodi F.S. O'Day S.J. McDermott D.F. et al.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010; 363: 711-723Crossref PubMed Scopus (11187) Google Scholar Caring for a patient presenting to the ED who is receiving a combination of multiple immune checkpoint inhibitors should prompt the emergency provider to consider immune-related adverse events as potential causes for suspicion symptoms. In addition to immune checkpoint inhibitors,16Burugu S. Dancsok A.R. Nielsen T.O. Emerging targets in cancer immunotherapy.Semin Cancer Biol. 2017; (http://doi.org/10.1016/j.semcancer.2017.10.001)Crossref PubMed Scopus (187) Google Scholar a second class of targeted immune-based therapy has been developed, chimeric antigen receptor T-cell therapy, which engineers the patient’s own T cells to recognize antigens on tumor cells.17Kalos M. Levine B.L. Porter D.L. et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Sci Transl Med. 2011; 3 (95ra73)Crossref Scopus (1795) Google Scholar Patients receiving this class of therapy also present with immune-related adverse events, and although the immune-related adverse events associated with chimeric antigen receptor T-cell therapy can be catastrophic (eg, encephalopathy, coma, fulminant hemophagocytic lymphohistiocytosis) and tend to occur closer to treatment initiation, similar considerations and recommendations apply. Nonspecific immunotherapies such as interferons18Corrales L. Gajewski T.F. Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer.Clin Cancer Res. 2015; 21: 4774-4779Crossref PubMed Scopus (120) Google Scholar and interleukins19Anestakis D. Petanidis S. Kalyvas S. et al.Mechanisms and applications of interleukins in cancer immunotherapy.Int J Mol Sci. 2015; 16: 1691-1710Crossref PubMed Scopus (56) Google Scholar are also being used. Patients receiving these therapies tend to present with nonspecific flulike symptoms.20Dhingra K. Talpaz M. Dhingra H.M. et al.A phase I trial of recombinant alpha-2a interferon (roferon-A) with weekly cisplatinum.Invest New Drugs. 1991; 9: 37-39Crossref PubMed Scopus (13) Google Scholar, 21Schwartz R.N. Stover L. Dutcher J.P. Managing toxicities of high-dose interleukin-2.Oncology (Williston Park). 2002; 16: 11-20PubMed Google Scholar For all patients receiving immunotherapy, a thorough medical history, high index of suspicion, and close communication with oncologists are essential to provide quality care. The provision of acute care for patients with cancer is increasingly becoming a major component of the care provided in the ED. In the new age of immune-based cancer treatments, emergency providers play an essential role in identifying subtle symptoms of immune-related adverse events as potential indicators of catastrophic treatment adverse effects. There exists an urgent need to change the approach of emergency providers to these patients, provide continuing education on immune-related adverse events, and update the ED-based cancer research agenda22Brown J. Grudzen C. Kyriacou D.N. et al.The emergency care of patients with cancer: setting the research agenda.Ann Emerg Med. 2016; 68: 706-711Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar to include immune therapies and immune-related adverse events. We are encouraged that emergency providers are taking the lead to further identify and address this need through new and innovative research6Majzoub I. Qdaisat A. Thein K.Z. et al.Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center.Ann Emerg Med. 2018; (http://doi.org/10.1016/j.annemergmed.2018.04.019)PubMed Google Scholar and research collaborations, such as the Comprehensive Oncologic Emergencies Research Network.23Greene J. CONCERN for cancer: new National Institutes of Health network to focus on cancer patients in the emergency department.Ann Emerg Med. 2015; 66: 13a-15aAbstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar However, it is crucial that we look beyond the ED and collaborate with our oncologist colleagues to provide the best-coordinated care possible. In conclusion, the rapidly changing cancer treatment landscape poses a new and daunting challenge that requires emergency providers to stay informed and vigilant in the nuanced presentations of immune-related adverse events. Emergency provider engagement with their local oncologists, continuing education opportunities on the topic, and the revision of the emergency research agenda priorities are essential in addressing this challenge. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer CenterAnnals of Emergency MedicineVol. 73Issue 1PreviewCancer immunotherapy is evolving rapidly and is transforming cancer care. During the last decade, immune checkpoint therapies have been developed to enhance the immune response; however, specific adverse effects related to autoimmunity are increasingly apparent. This study aims to fill the knowledge gap related to the spectrum of immune-related adverse effects among cancer patients visiting emergency departments (EDs). Full-Text PDF" @default.
• W2890600126 created "2018-09-27" @default.
• W2890600126 creator A5000159448 @default.
• W2890600126 creator A5006468163 @default.
• W2890600126 creator A5080774339 @default.
• W2890600126 date "2019-01-01" @default.
• W2890600126 modified "2023-10-17" @default.
• W2890600126 title "Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment" @default.
• W2890600126 cites W1905337938 @default.
• W2890600126 cites W2035730263 @default.
• W2890600126 cites W2086172507 @default.
• W2890600126 cites W2097995306 @default.
• W2890600126 cites W2140825405 @default.
• W2890600126 cites W2153825039 @default.
• W2890600126 cites W2167550136 @default.
• W2890600126 cites W2198067008 @default.
• W2890600126 cites W2284502361 @default.
• W2890600126 cites W2468004496 @default.
• W2890600126 cites W2530004119 @default.
• W2890600126 cites W2603361374 @default.
• W2890600126 cites W2607144338 @default.
• W2890600126 cites W2753839077 @default.
• W2890600126 cites W2761081415 @default.
• W2890600126 cites W2761191882 @default.
• W2890600126 cites W2786816161 @default.
• W2890600126 cites W2800543236 @default.
• W2890600126 cites W2802509580 @default.
• W2890600126 cites W2806838035 @default.
• W2890600126 cites W52103172 @default.
• W2890600126 doi "https://doi.org/10.1016/j.annemergmed.2018.08.421" @default.
• W2890600126 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6377798" @default.
• W2890600126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30243546" @default.
• W2890600126 hasPublicationYear "2019" @default.
• W2890600126 type Work @default.
• W2890600126 sameAs 2890600126 @default.
• W2890600126 citedByCount "8" @default.
• W2890600126 countsByYear W28906001262020 @default.
• W2890600126 countsByYear W28906001262021 @default.
• W2890600126 countsByYear W28906001262022 @default.
• W2890600126 countsByYear W28906001262023 @default.
• W2890600126 crossrefType "journal-article" @default.
• W2890600126 hasAuthorship W2890600126A5000159448 @default.
• W2890600126 hasAuthorship W2890600126A5006468163 @default.
• W2890600126 hasAuthorship W2890600126A5080774339 @default.
• W2890600126 hasBestOaLocation W28906001261 @default.
• W2890600126 hasConcept C121608353 @default.
• W2890600126 hasConcept C126322002 @default.
• W2890600126 hasConcept C17744445 @default.
• W2890600126 hasConcept C177713679 @default.
• W2890600126 hasConcept C199539241 @default.
• W2890600126 hasConcept C2779473830 @default.
• W2890600126 hasConcept C3019816032 @default.
• W2890600126 hasConcept C71924100 @default.
• W2890600126 hasConceptScore W2890600126C121608353 @default.
• W2890600126 hasConceptScore W2890600126C126322002 @default.
• W2890600126 hasConceptScore W2890600126C17744445 @default.
• W2890600126 hasConceptScore W2890600126C177713679 @default.
• W2890600126 hasConceptScore W2890600126C199539241 @default.
• W2890600126 hasConceptScore W2890600126C2779473830 @default.
• W2890600126 hasConceptScore W2890600126C3019816032 @default.
• W2890600126 hasConceptScore W2890600126C71924100 @default.
• W2890600126 hasFunder F4320332161 @default.
• W2890600126 hasFunder F4320337338 @default.
• W2890600126 hasIssue "1" @default.
• W2890600126 hasLocation W28906001261 @default.
• W2890600126 hasLocation W28906001262 @default.
• W2890600126 hasLocation W28906001263 @default.
• W2890600126 hasLocation W28906001264 @default.
• W2890600126 hasOpenAccess W2890600126 @default.
• W2890600126 hasPrimaryLocation W28906001261 @default.
• W2890600126 hasRelatedWork W1506200166 @default.
• W2890600126 hasRelatedWork W1995515455 @default.
• W2890600126 hasRelatedWork W2048182022 @default.
• W2890600126 hasRelatedWork W2080531066 @default.
• W2890600126 hasRelatedWork W2604872355 @default.
• W2890600126 hasRelatedWork W2748952813 @default.
• W2890600126 hasRelatedWork W2899084033 @default.
• W2890600126 hasRelatedWork W3031052312 @default.
• W2890600126 hasRelatedWork W3032375762 @default.
• W2890600126 hasRelatedWork W3108674512 @default.
• W2890600126 hasVolume "73" @default.
• W2890600126 isParatext "false" @default.
• W2890600126 isRetracted "false" @default.
• W2890600126 magId "2890600126" @default.
• W2890600126 workType "article" @default.